Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome

Acute Kidney Injury Clinical Trial

Official title:

A Multi-Centre, Randomised, Open-Label, Phase II Study of Ambrisentan in Patients With Hepatorenal Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06256432
• Other study ID #: N-003-CRD005
• Status: Recruiting
• Phase: Phase 2
• Start date: April 17, 2024
• Est. completion date: June 2025

Study information

• Verified date: June 2024
• Source: Noorik Biopharmaceuticals AG
• Contact: Iker Navarro, MD
• Phone: +41 76 398 7007
• Email: iker.navarro[@]noorik.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with advanced cirrhosis of the liver develop kidney problems occasionally. This condition is called Hepatorenal Syndrome, requires hospitalization and frequently results in death.

The goal of this clinical trial is to test whether the administration of low doses of ambrisentan can help patients with Hepatorenal Syndrome and to determine if it is safe. Ambrisentan is a drug that is approved for the treatment of high blood pressure in the lungs at higher doses.

This clinical trial will compare the safety and effects of ambrisentan to another drug called terlipressin, which is commonly used to treat patients with hepatorenal syndrome.

The main questions the clinical trial aims to answer are:

• Does ambrisentan help the kidney function of the patient?

• Does ambrisentan help prevent death in patients with Hepatorenal Syndrome?

• Does ambrisentan prevent Hepatorenal Syndrome from reappearing?

While in the hospital, trial participants will receive either one of two doses of ambrisentan or terlipressin. If in the first 4 days, ambrisentan is not helpful, the patient may be eligible to receive terlipressin. Patients assigned to receive ambrisentan will continue taking this medication at home after leaving the hospitals and until they complete 60 days of treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 45
• Est. completion date: June 2025
• Est. primary completion date: March 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Written Informed consent prior to any study-related procedures.

• Age = 18 years and = 60 years.

• Male or non-pregnant, non-lactating female. Women of child-bearing potential must have a confirmed negative serum pregnancy test at the time of screening and must use a highly effective contraceptive method throughout the study such as combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tube occlusion, vasectomised partner, and sexual abstinence and until one month after completing treatment with the study medication. In the case of hormonal contraception, women should have been on a stable regimen for a minimum of three months before study enrolment. Women not of child-bearing potential include post-menopausal females (defined as having a history of amenorrhea for at least one year) or a documented status as being surgically sterile (hysterectomy, bilateral oophorectomy, tubal ligation/salpingectomy). Men must use an effective contraception method (i.e., condom + diaphragm/spermicidal gel or foam, or vasectomy), and should not donate semen during the study. Men are considered to be fertile from the time of puberty, except for those men with permanent sterility secondary to bilateral orchiectomy.

• Cirrhosis of the liver by laboratory examination, clinical history or biopsy.

• History of ascites.

• Increase in serum creatinine = 0.3 mg/dl (26.5 µmol/L) from a value obtained in the 7 days prior to admission, OR a serum creatinine = 1.5 mg/dl (132.6 µmol/L) and is = 1.5-fold above the most recent and lowest value obtained in the last 3 months.

• Subject has completed 48 hours of diuretic withdrawal and plasma volume expansion with albumin prior to study inclusion (e.g., 1 g/kg for first 24 hours and not to exceed 100 g, followed by 20-40 g in second 24 hours).

• No sustained improvement in renal function during 48 hours of both diuretic withdrawal and plasma volume expansion with albumin, defined as a decrease in serum creatinine of less than 20% from initial value.

• Planned treatment for the management of HRS consisting of terlipressin and concomitant albumin.

Exclusion Criteria:

• Serum creatinine > 5 mg/dL (442 µmol/L) at the end of the 48-hour diuretic withdrawal and plasma volume expansion with albumin period.

• Mean arterial pressure (MAP) < 60 mmHg.

• Large Volume Paracentesis (LVP) in the 3 days prior to screening.

• Sepsis, uncontrolled bacterial infection or less than 2 days anti-infective therapy for documented or suspected bacterial infection.

• Total bilirubin > 8 mg/dL (137 µmol/L).

• Serum sodium < 130 mmol/L.

• International Normalised Ratio (INR) = 3.5.

• Proteinuria = 500 mg/dL.

• Microhaematuria > 50 red blood cells per high power field.

• Clinically significant casts on urinalysis, including granular casts.

• History or evidence of obstructive uropathy or parenchymal renal disease on ultrasound or other imaging.

• Subject with a recent history of circulatory shock defined as MAP < 60 mmHg within 5 days prior to screening requiring vasopressors or subjects requires circulatory support with vasopressors during screening.

• Subject requiring oxygen supplementation or mechanical ventilation.

• Recent exposure to nephrotoxic agents or exposure to radiographic contrast agents within 72 hrs prior to screening.

• Superimposed acute liver failure/injury due to factors other than alcohol, including acute viral hepatitis, drugs, medications (e.g., acetaminophen), or other toxins (e.g., mushroom [Amanita] poisoning).

• Severe cardiovascular disease, including, but not limited to, unstable angina, pulmonary oedema, congestive heart failure (NYHA = II), or persisting symptomatic peripheral vascular disease, myocardial infarction or stable chronic angina within the past 12 months, or any other cardiovascular disease judged by the Investigator to be severe.

• Subject has a history of Transjugular Intrahepatic Portosystemic shunt (TIPS).

• Subject with acute variceal bleeding at the time of screening who may undergo pre-emptive TIPS or is anticipated to be treated with terlipressin.

• Current or recent Renal Replacement Therapy (RRT) within 30 days of enrolment, or anticipation of RRT in the next 3 days after screening.

• Hepatocellular Carcinoma (HCC) beyond the Milan criteria or other malignancy affecting survival beyond 6 months.

• Participation in a study of an investigational medical product or device within the last 30 days preceding screening.

• Hepatic Encephalopathy with West Haven Grade III or IV.

• Current or recent (30 days prior to enrolment) treatment with endothelin receptor antagonists, including ambrisentan. Subjects receiving midodrine and/or octreotide may be enrolled. Midodrine and octreotide treatment must be stopped prior to enrolment.

• Estimated life expectancy of less than 3 days.

• Known allergy or sensitivity to ambrisentan or propylene glycol.

• History of Idiopathic Pulmonary Fibrosis.

• Subject is unable or unwilling to follow instructions or comply with study procedures.

Related Conditions & MeSH terms

• Acute Kidney Injury
• Ascites
• Ascites Hepatic
• Hepatorenal Syndrome
• Liver Cirrhosis
• Syndrome

Intervention

Drug:
• Ambrisentan
Endothelin receptor antagonist
• Terlipressin
Terlipressin

Locations

Country	Name	City	State
India	Aster CMI Hospital	Bangalore	Karnataka
India	Ganesh Shankar Vidyarthi Memorial (GSVM) Medical College	Kanpur	Uttar Pradesh
India	Medanta Multi Super Specialty Hospital	Lucknow	Uttar Pradesh
India	Sir HN Reliance Hospital Foundation	Mumbai	Maharashtra
India	All India Institute of Medical Sciences	New Delhi	Delhi

Sponsors (1)

Lead Sponsor	Collaborator
Noorik Biopharmaceuticals AG

Country where clinical trial is conducted

India, 

References & Publications (9)

Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, Moreau R, Jalan R, Sarin SK, Piano S, Moore K, Lee SS, Durand F, Salerno F, Caraceni P, Kim WR, Arroyo V, Garcia-Tsao G; International Club of Ascites. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015 Apr;64(4):531-7. doi: 10.1136/gutjnl-2014-308874. Epub 2015 Jan 28. No abstract available. — View Citation

Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension. 2009 Jul;54(1):113-9. doi: 10.1161/HYPERTENSIONAHA.109.132670. Epub 2009 Jun 8. — View Citation

Mindikoglu AL, Weir MR. Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis. Am J Nephrol. 2013;38(4):345-54. doi: 10.1159/000355540. Epub 2013 Oct 5. — View Citation

Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med. 1992 Dec 17;327(25):1774-8. doi: 10.1056/NEJM199212173272502. — View Citation

Moore K. Endothelin and vascular function in liver disease. Gut. 2004 Feb;53(2):159-61. doi: 10.1136/gut.2003.024703. — View Citation

Ring-Larsen H. Renal blood flow in cirrhosis: relation to systemic and portal haemodynamics and liver function. Scand J Clin Lab Invest. 1977 Nov;37(7):635-42. doi: 10.3109/00365517709100657. — View Citation

Soper CP, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet. 1996 Jun 29;347(9018):1842-3. No abstract available. — View Citation

Wong F, Moore K, Dingemanse J, Jalan R. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology. 2008 Jan;47(1):160-8. doi: 10.1002/hep.21940. — View Citation

Zipprich A, Gittinger F, Winkler M, Dollinger MM, Ripoll C. Effect of ET-A blockade on portal pressure and hepatic arterial perfusion in patients with cirrhosis: A proof of concept study. Liver Int. 2021 Mar;41(3):554-561. doi: 10.1111/liv.14757. Epub 2021 Jan 5. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in estimated GFR (eGFR) from baseline	As determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula	4 days
Secondary	Proportion of patients achieving Hepatorenal Syndrome reversal	Reversal defined as two consecutive serum creatinine values < 1.5 mg/dL (132 µmol/L) within 24 hours	14 days
Secondary	Proportion of subjects experiencing Hepatorenal Syndrome recurrence	Recurrence defined as the appearance of Hepatorenal Syndrome satisfying all clinical trial entry criteria	60 days
Secondary	Overall survival	Proportion of participants alive in each treatment arm	60 days